The Effects of Ramipril on Clinical Symptoms in Patients With Peripheral Arterial Disease
Primary Purpose
Peripheral Arterial Disease
Status
Completed
Phase
Phase 4
Locations
Australia
Study Type
Interventional
Intervention
Ramipril
Sponsored by
About this trial
This is an interventional treatment trial for Peripheral Arterial Disease
Eligibility Criteria
Inclusion Criteria: Ankle-brachial index of <0.9 at rest in at least one leg History of intermittent claudication (unilateral or bilateral) which was stable for 6 months Evidence of superficial femoral artery stenosis or occlusion on duplex scan Blood pressure <=160/90 mmHg Stable medication regimen for at least 6 months and not previously treated with ACE inhibitors Exclusion Criteria: Limiting coronary artery disease Renal Failure History of hypertension History of type 2 diabetes mellitus
Sites / Locations
- Alfred Hospital
Outcomes
Primary Outcome Measures
Time to onset of claudication
Total exercise time during a standard treadmill test
Walking ability measured using the standard Walking Impairment Questionnaire
Secondary Outcome Measures
Leg Blood Flow using Duplex Ultrasound
Full Information
NCT ID
NCT00168467
First Posted
September 9, 2005
Last Updated
January 28, 2009
Sponsor
Baker Heart Research Institute
1. Study Identification
Unique Protocol Identification Number
NCT00168467
Brief Title
The Effects of Ramipril on Clinical Symptoms in Patients With Peripheral Arterial Disease
Official Title
The Effects of Ramipril on Clinical Symptoms in Patients With Peripheral Arterial Disease
Study Type
Interventional
2. Study Status
Record Verification Date
January 2009
Overall Recruitment Status
Completed
Study Start Date
undefined (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
undefined (undefined)
3. Sponsor/Collaborators
Name of the Sponsor
Baker Heart Research Institute
4. Oversight
5. Study Description
Brief Summary
One important clinical challenge in older individuals is maintaining mobility in the absence of pain. Peripheral arterial disease affects up to 12% of adults over 50 and impairs quality of life due to intermittent claudication causing pain and limiting mobility.
Conventional therapies have only modest effect in improving symptoms. The investigators hypothesise that angiotensin converting enzyme inhibition (with ramipril), which causes arterial vasodilation, also improves clinical symptoms in patients with peripheral arterial disease.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Peripheral Arterial Disease
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
Double
Allocation
Randomized
Enrollment
40 (false)
8. Arms, Groups, and Interventions
Intervention Type
Drug
Intervention Name(s)
Ramipril
Primary Outcome Measure Information:
Title
Time to onset of claudication
Title
Total exercise time during a standard treadmill test
Title
Walking ability measured using the standard Walking Impairment Questionnaire
Secondary Outcome Measure Information:
Title
Leg Blood Flow using Duplex Ultrasound
10. Eligibility
Sex
All
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Ankle-brachial index of <0.9 at rest in at least one leg
History of intermittent claudication (unilateral or bilateral) which was stable for 6 months
Evidence of superficial femoral artery stenosis or occlusion on duplex scan
Blood pressure <=160/90 mmHg
Stable medication regimen for at least 6 months and not previously treated with ACE inhibitors
Exclusion Criteria:
Limiting coronary artery disease
Renal Failure
History of hypertension
History of type 2 diabetes mellitus
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Bronwyn A Kingwell, PhD
Organizational Affiliation
Baker Heart Research Institute
Official's Role
Principal Investigator
Facility Information:
Facility Name
Alfred Hospital
City
Melbourne
State/Province
Victoria
ZIP/Postal Code
3004
Country
Australia
12. IPD Sharing Statement
Citations:
PubMed Identifier
16670135
Citation
Ahimastos AA, Lawler A, Reid CM, Blombery PA, Kingwell BA. Brief communication: ramipril markedly improves walking ability in patients with peripheral arterial disease: a randomized trial. Ann Intern Med. 2006 May 2;144(9):660-4. doi: 10.7326/0003-4819-144-9-200605020-00009.
Results Reference
result
Learn more about this trial
The Effects of Ramipril on Clinical Symptoms in Patients With Peripheral Arterial Disease
We'll reach out to this number within 24 hrs